Oncology and Therapy最新文献

{"title":"Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy.","authors":"Jorge J Nieva, Xuejun Wang, Deborah Doroshow, Leslie Servidio, Miranda Cooper, Yan Kwan Lau, Pritesh S Karia, Jacqulyne Robichaux","doi":"10.1007/s40487-025-00395-7","DOIUrl":"10.1007/s40487-025-00395-7","url":null,"abstract":"<p><strong>Introduction: </strong>Osimertinib is recommended, alongside afatinib, as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) with atypical mutations in the epidermal growth factor receptor gene (EGFR), a population for whom real-world data are limited. We present outcomes and subsequent treatment patterns for this population in routine US practice.</p><p><strong>Methods: </strong>Medical records from a manually curated oncology database were analyzed for adults with stage IIIB-IV NSCLC harboring atypical EGFR mutations, treated with first-line osimertinib (April 2018-March 2020). Data were analyzed overall and by EGFR mutation subgroups: compound EGFR mutations, comprising classical (exon [Ex] 19 deletion or L858R) and atypical (G719X, L861Q, S768I, E709X, Ex19 insertions, or Ex18-25 duplications) mutations or de novo T790M only (group A), and atypical EGFR mutations only (group B). Outcomes included real-world progression-free survival (rwPFS) and overall survival (OS).</p><p><strong>Results: </strong>A total of 55 patients were included in the study (female 76%/male 24%; group A, n = 20; group B, n = 35). After a median follow-up of 11 months, median (95% confidence interval) rwPFS and OS, respectively, were 8.8 (5.5-17.2) and 28.5 months (11.4-41.8) overall, 20.3 (10.0-44.5) and 42.5 months (27.0-not estimable) in group A, and 6.6 (4.9-24.8) and 20.0 months (9.2-32.9) in group B. At follow-up, 13% of patients (n = 7) remained on first-line osimertinib (group A, 30%; group B, 3%), 54% (n = 30) had discontinued due to death (group A, 40%; group B, 63%), and 33% (n = 18) had received subsequent treatment (group A, 30%; group B, 34%), most commonly osimertinib combinations (28%; n = 5).</p><p><strong>Conclusions: </strong>First-line osimertinib may provide real-world clinical benefits for patients with advanced NSCLC with atypical EGFR mutations, with results suggesting greater benefit in those harboring compound EGFR mutations.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"225-240"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145483274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qualitative Interviews on the Experience of Orally vs. Intramuscularly Administered Endocrine Therapy for Advanced Breast Cancer: Patient and Healthcare Provider Perspectives.","authors":"Rebecca M Speck, Gale Harding, Aarti R Chawla, Christine R Agius, Shakeela W Bahadur, Kathryn Hudson, Mohammed A Jaloudi, Ritesh Parajuli, Gregory A Vidal, Elizabeth D Bacci","doi":"10.1007/s40487-025-00408-5","DOIUrl":"10.1007/s40487-025-00408-5","url":null,"abstract":"<p><strong>Introduction: </strong>The selective estrogen receptor degraders (SERD) have proven to be an effective treatment option for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). The orally administered next-generation SERDs may be more tolerable and a preferred alternative to the intramuscularly (IM) administered fulvestrant. This study sought to identify patient and healthcare provider (HCP) perspectives on preferences, benefits, burdens, and ease of adherence of oral and IM endocrine therapy (ET).</p><p><strong>Methods: </strong>Non-interventional, qualitative interviews were conducted in the USA, among adult patients with ER+ HER2- ABC and oncology HCPs. Eligible patients and HCPs had experience with both oral ET and fulvestrant within the past 3 years. One-on-one semi-structured interviews lasted up to 60 min.</p><p><strong>Results: </strong>We interviewed 25 patients and 20 HCPs. The mean time from BC diagnosis was 12.6 years (standard deviation 8.4); 18 patients (72%) were currently receiving IM and 7 (28%) oral ET. Sixteen patients (64%) preferred oral ET, mainly owing to convenience (13/16, 81%), which was considered the main benefit (22/25, 88%); side effects were a common burden (18/25, 72%). Seven patients preferred IM ET, mainly owing to the monthly injection frequency (6/7, 85%). The primary benefit of IM ET was not having to remember daily dosing (12/22, 55%), and main burdens were injection pain (21/25, 84%) and travel to receive injection (14/22, 64%). Most patients (23/25, 92%) experienced ease of adherence to oral ET. HCPs perspectives were largely aligned to the patients' experiences.</p><p><strong>Conclusion: </strong>Patients with ER+ HER2- ABC in this study preferred oral to IM ET owing to convenience, and disliked the pain associated with IM ET and travel to receive injections. Compared to IM fulvestrant, oral SERDs may offer an alternative with less burden on the lives of people living with cancer.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"327-349"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145669902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics, Treatment Patterns, and Outcomes of Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Analysis of Health Insurance Claims Data in Germany.","authors":"Jennifer Stuart, Evi Zhuleku, Antje Mevius, Patrick Squires, Chethan Ramamurthy, Barthold Deiters, Mehmet Burcu","doi":"10.1007/s40487-025-00413-8","DOIUrl":"10.1007/s40487-025-00413-8","url":null,"abstract":"<p><strong>Introduction: </strong>Muscle-invasive bladder cancer (MIBC) is an aggressive form of bladder cancer characterized by high rates of metastasis and recurrence. Given recent advances in the treatment landscape, real-world evidence on current treatment patterns and outcomes remains limited, particularly outside of the USA. This study aimed to describe characteristics, treatment patterns, and outcomes of patients with MIBC undergoing radical cystectomy (RC) in a contemporary real-world setting in Germany.</p><p><strong>Methods: </strong>Adult patients with bladder cancer (BC) who underwent RC between October 2021 and June 2023 were identified from two German claims databases (AOK PLUS, GWQ). Patients with partial cystectomy, secondary malignant neoplasms, immunotherapies for metastatic disease prior to RC, radiotherapy, or in situ disease ≤ 6 months pre-RC were excluded. Patient characteristics and treatment patterns (neoadjuvant [NAT, ≤ 6 months pre-RC] and adjuvant periods [AT, ≤ 6 months post-RC]) were investigated in a descriptive analysis. Time to recurrence (from RC until end of follow-up [study period end: Dec 31, 2023]) was assessed as an exploratory outcome.</p><p><strong>Results: </strong>The study sample included 319 patients from AOK PLUS (n = 243 male patients, n = 76 female patients; mean age 71.4 ± 9.7 years) and 273 patients from GWQ (n = 227 male patients, n = 46 female patients; mean age 68.6 ± 10.1 years). Surgery without NAT/AT was the most common treatment (75.9% AOK, 74.0% GWQ). NAT and AT therapy utilization was low (NAT: 12.5% AOK, 17.2% GWQ; AT: 12.5% AOK, 12.1% GWQ; NAT and AT: 0.9% AOK, 3.3% GWQ). The most common adjuvant therapies received were chemotherapy (8.5% AOK, 7.0% GWQ) followed by immunotherapy/nivolumab (3.8% AOK, 4.8% GWQ), while < 2.5% received radiotherapy. The 12- and 24-month recurrence-free survival rates were 76.5% and 67.2% (AOK) and 73.7% and 69.6% (GWQ), respectively.</p><p><strong>Conclusion: </strong>The most prevalent treatment approach for MIBC was RC alone (in the absence of NAT or AT). The uptake of new therapeutic options, such as adjuvant nivolumab, in the real world was low, highlighting underutilization of available therapies.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"373-388"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer.","authors":"Sarah Sammons, Denise A Yardley, Priyanka Sharma, Vijayakrishna K Gadi, Mark Pegram, Purnima Pathak, Huilin Hu, Gary Sopher, Peter A Fasching","doi":"10.1007/s40487-025-00394-8","DOIUrl":"10.1007/s40487-025-00394-8","url":null,"abstract":"","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"19-25"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient and Physician Perspectives on Prostate Cancer Data Presented at ASCO 2025.","authors":"Pedro Barata, Tom Hulsey","doi":"10.1007/s40487-025-00403-w","DOIUrl":"10.1007/s40487-025-00403-w","url":null,"abstract":"<p><p>In this plain language podcast, highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 are discussed. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in the field of prostate cancer. This podcast is intended to broaden the reach of complex data and insights from ASCO 2025 to a broader audience, including non-specialists, helping enable better informed treatment decisions between patients and healthcare professionals. The authors begin with a brief summary of the current diagnosis and treatment landscape for patients with prostate cancer, before discussing three topics: personalized therapy for hormone-sensitive prostate cancer; new therapeutics for hormone-resistant prostate cancer; and patient quality of life and supportive care. For hormone-sensitive prostate cancer, biomarker-driven strategies based on genetic and molecular changes in tumor biology and imaging are emerging to help identify which patients may benefit from more targeted treatments. These personalized strategies provide hope to initiate treatment earlier, ultimately preventing disease progression to hormone resistance. For patients who have progressed to difficult-to-treat hormone-resistant prostate cancer, early clinical trials show promise. Novel approaches including radioligands, antibody-drug conjugates, bispecific T cell engagers, and therapy combinations are expanding future treatment options. Finally, mental health screening, educational tools to improve patients' awareness of their disease, and remote health monitoring may help improve the quality of life of patients and their families/caregivers, signposting them to appropriate supportive care. Data presented at ASCO 2025 highlights a shift in the treatment and management of prostate cancer towards a more personalized approach and further amplifies the need to consider individual patient populations. A glossary of abbreviations and terms used in this podcast is provided in the electronic supplementary material. Podcast Audio (MP4 175328 KB).</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"51-62"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145606675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer.","authors":"Margarita Majem, Busyamas Chewaskulyong, Zanete Zvirbule, Ki Hyeong Lee, Ernesto Korbenfeld, Jaroslaw Kolb-Sielecki, Amparo Yovanna Castro Sanchez, Alberto Bustillos, Luis Herraez-Baranda, Xiaoyan Liu, Sang-We Kim, Federico Cappuzzo","doi":"10.1007/s40487-025-00402-x","DOIUrl":"10.1007/s40487-025-00402-x","url":null,"abstract":"<p><strong>Introduction: </strong>The primary analysis of IMscin002 (NCT05171777) demonstrated that most patients preferred atezolizumab subcutaneous (SC) administration over intravenous (IV) administration; we report patient preference according to baseline characteristics, mean injection duration, and cumulative number of SC injections at each center from IMscin002.</p><p><strong>Methods: </strong>In this phase 2, randomized, open-label, crossover trial, patients aged ≥18 years, with EGFR/ALK wild-type tumors and either PD-L1+ (≥ 1%) resected non-small cell lung cancer (NSCLC) (stage 2, 3a, or selected 3b; AJCC 8th edition) with prior chemotherapy and no evidence of recurrence, or untreated PD-L1-high (≥ 50%) stage 4 NSCLC were eligible. Patients, randomized 1:1, received atezolizumab IV or SC for three cycles before switching to the alternative formulation for another three cycles. Patients chose a formulation for the continuation period after cycle 6.</p><p><strong>Primary endpoint: </strong>patient preference for atezolizumab SC/IV.</p><p><strong>Results: </strong>Among 179 patients randomized, demographics and characteristics were generally balanced between arms. Overall, 87/123 patients (70.7%) preferred atezolizumab SC, of whom 86.2% had a very/fairly strong preference compared with 69.2% of patients who preferred IV (n = 26/123, 21.1%). Patient preference for atezolizumab SC was independent of baseline characteristics and mean injection duration. A higher proportion of preference was seen in patients aged > 74 years (87.5%). A trend for a greater number of patients preferring atezolizumab SC over IV was seen in patients at centers where a higher number of cumulative injections (> 47 to ≤ 164) were administered before preference disclosure.</p><p><strong>Conclusions: </strong>Most patients preferred atezolizumab SC regardless of baseline characteristics, mean injection duration, and cumulative number of SC injections. The trend for a stronger preference was higher among patients who preferred SC than those who preferred IV. Our findings suggest that the proportion of preference for atezolizumab SC over IV is highest in patients aged > 74 years, and that administrator's experience could be an important factor influencing patient preference.</p><p><strong>Clinical trial registration number: </strong>NCT05171777.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"313-326"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145606690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Comorbidities in Treatment Decision-Making across the Spectrum of Prostate Cancer: A Podcast.","authors":"Peter Whelan, Kirsty Balachandran, Kenrick Ng","doi":"10.1007/s40487-025-00407-6","DOIUrl":"10.1007/s40487-025-00407-6","url":null,"abstract":"<p><p>Effective management of prostate cancer requires an approach that integrates oncological intent with careful consideration of coexisting comorbidities and functional reserve. This podcast explores how chronic health conditions, frailty and quality-of-life factors influence therapeutic choices across the disease continuum. In localised disease, long-term data demonstrating comparable survival between surgery, radiotherapy and active monitoring have reframed the rationale for radical intervention. Treatment decisions are now increasingly guided by competing health risks, anticipated life expectancy and patient preference. In advanced disease, treatment intensification with systemic combination therapy has extended survival but introduced new complexity. The cardiovascular, metabolic and cognitive toxicities of androgen deprivation therapy (ADT) necessitate individualised consideration of intermittent therapy or de-escalation for patients with substantial comorbidity. With the expanding use of triplet regimens in metastatic hormone-sensitive disease, assessing physiological rather than chronological age has become essential. The discussion further highlights the role of structured oncogeriatric assessment in optimising care. Tools such as the Rockwood Clinical Frailty Scale, G8 screening tool and comprehensive geriatric assessment (CGA) provide a systematic framework for evaluating frailty, polypharmacy, cognition and function, supporting balanced decisions about treatment escalation and supportive interventions. Collectively, the dialogue underscores a shift towards holistic, multidisciplinary decision-making that aligns cancer control with broader health, independence and wellbeing. Embedding frailty-informed assessment into prostate cancer pathways represents a necessary evolution towards truly personalised care. Podcast Video (MP4 314221 KB).</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"63-71"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Early and Metastatic Breast Cancer: A Consensus Statement from Oncologists in Saudi Arabia.","authors":"Sabah Alaklabi, Sadal Al Refaei, Omalkhair Abualkhair, Atlal Abusanad, Saad Akhtar, Meteb AlFoheidi, Marwan Al-Hajeili, Taher Al-Tweigeri, Hashem Alhashem, Roula Almufti, Adher Alsayed, Ahmed Alshehri, Abdullah Altwairgi, Meshari Alzahrani, Bassam Basulaiman, Leonidas Chelis, Sherif Elsammani, Ibrahim Madkhali, Essam Murshid, Ahmed Refae, Kauser Suleman, Nafisa Abdelhafiz, Sharif Kullab","doi":"10.1007/s40487-025-00404-9","DOIUrl":"10.1007/s40487-025-00404-9","url":null,"abstract":"<p><strong>Introduction: </strong>In the Kingdom of Saudi Arabia, there is a lack of up-to-date clinical guidelines on the treatment of early-stage or metastatic breast cancer (BC) that are relevant to local resource and financial constraints. Therefore, we aimed to develop consensus statements to provide practical guidance for general oncologists on BC management in the Kingdom that support fair and rational decision-making across institutions.</p><p><strong>Methods: </strong>A panel of medical oncologist experts from the Kingdom of Saudi Arabia was convened. Based on a pragmatic literature review, 35 statements were drafted by two of the participating oncologist experts (S. Alaklabi and M. Alzahrani) that focused on clinical scenarios with lacking/contradictory data while taking into account healthcare resource availability. A modified Delphi process was used (consensus threshold was ≥ 70%); the first round of voting was online and second-round voting was conducted in-person.</p><p><strong>Results: </strong>Twenty-six panelists voted on each statement in Round 1 and 19 to 23 panelists (not all voted on every statement) voted in Round 2. Consensus was reached on 13 of 20 statements for early BC and on seven of 15 statements for metastatic BC (MBC). Statements on early BC defined the use of adjuvant cyclin-dependent kinase-4/6 inhibitors, neoadjuvant hormonal therapy duration (statements S6-7), and the management of triple-negative BC, where there is residual disease or pathologic complete response is not achieved after neoadjuvant chemoimmunotherapy. Statements on MBC defined the use of trastuzumab deruxtecan in patients with hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-low disease or in patients with HER2+ MBC and brain metastases/leptomeningeal disease, and the use of sacituzumab govitecan in hormone receptor-positive/negative HER2-low MBC. Antibody-drug conjugate sequencing and oligoprogression were also covered.</p><p><strong>Conclusion: </strong>The consensus statements provide expert guidance for medical oncologists, and it is hoped these statements will help unify clinical practice across the Kingdom.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"291-312"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145557494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Several Considerations on the Pathology, Treatment, and Prognosis of Laryngeal NUT Carcinoma.","authors":"Andrés Coca-Pelaz, Alfio Ferlito","doi":"10.1007/s40487-026-00422-1","DOIUrl":"10.1007/s40487-026-00422-1","url":null,"abstract":"<p><p>Laryngeal NUT carcinoma (NC) is an exceptionally rare and highly aggressive malignancy defined by rearrangements of the NUTM1 gene, most commonly involving BRD4. Owing to its morphologic overlap with poorly differentiated squamous cell carcinoma, this entity is frequently underrecognized in routine practice, particularly in the larynx. In this editorial, we summarize current knowledge on the pathology, molecular biology, treatment strategies, and prognosis of laryngeal NC, with particular emphasis on diagnostic pitfalls and clinical outcomes reported in literature. Available evidence highlights a strikingly aggressive clinical course, with most patients experiencing early disease progression and death within the first year of diagnosis, despite multimodal treatment approaches. Rare cases of long-term survival suggest underlying biological heterogeneity, potentially related to fusion subtype. Given the absence of standardized treatment protocols, most reported patients have been managed with an aggressive multimodal approach combining surgery and (chemo)radiation; however, outcomes remain poor. Therefore, early recognition and systematic NUT immunohistochemical testing in poorly differentiated laryngeal carcinomas, especially in younger patients, are critical. Advances in molecularly targeted therapies may offer future opportunities to improve outcomes in this devastating disease.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"9-17"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social Determinants of Health in Metastatic Breast Cancer Care: A Podcast Exploring Challenges and Opportunities in the United States and Canada.","authors":"Monique Gary, Karen Gelmon, Joanne C Ryan","doi":"10.1007/s40487-025-00406-7","DOIUrl":"10.1007/s40487-025-00406-7","url":null,"abstract":"<p><p>The influence of social determinants of health (SDOH) on clinical outcomes for patients with cancer has become increasingly clear in recent years. This podcast, featuring a breast surgeon from the USA and a breast medical oncologist from Canada, provides updated definitions of SDOH, discusses the importance of assessing for SDOH-related barriers to optimal, equitable care for patients with metastatic breast cancer (mBC), and offers practical solutions that individual practices can implement. While this discussion is focused on the USA and Canada, SDOH factors are salient for healthcare providers around the world, irrespective of the healthcare systems deployed in their individual countries. Key SDOH that can impact care or outcomes for patients living with mBC are discussed by the hosts, including patient socioeconomic status, transportation logistics, health literacy, and social support. The importance of establishing trust between care provider and patient is also examined, especially for racial and ethnic minorities who have earned concerns and mistrust of healthcare systems. To aid practices in addressing SDOH-related barriers, various resources are identified, including free screening tools and support offered by patient advocacy and nonprofit organizations. Despite the scope of SDOH-related challenges, practices can collaborate to achieve progress toward equitable care for patients with mBC. Podcast Video (MP4 122704 kb).</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"81-89"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145764076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}